- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00474331
Gene Mutations and Orthopaedic Symptoms Correlation of Multiple Hereditary Exostoses: Multicentre Project
Genotype-Phenotype Correlation of Multiple Hereditary Exostoses: Multicentre Project
Study Overview
Status
Conditions
Detailed Description
Subject Recruitment:
New patients presenting with HME will be identified through the offices and clinics of British Columbia Children's Hospital Orthopaedic Department. All potential participants will be educated about the study's rationale, purpose, and procedures and informed consent will be obtained.
Demographics:
All probands (affected patient), their first degree family members and extended family members willing to participate in the study will be interviewed. Information including age, gender, ethnic origin, family history, symptoms, complications and previous surgery will be elucidated.
Phenotype:
Affected patients will have their osteochondroma(s) mapped for location, size, morphology, and symptoms. A total of seventy-five phenotypic parameters divided into four major data categories will be collected. The first two categories are accumulated from physical examinations and include stature and limb segment lengths (15 (x2 for left and right). The other two categories, lesion quality (19 parameters) and limb alignment and deformity (26 parameters) will be drawn from radiographic examinations which are part of the patient's current care. All available xrays will be reviewed and the exostoses characterized radiographically. This will establish the patient's genotype.
Genotype:
Each participant whose genotype is unknown will have a 10 cc. blood sample collected at BC Children's Hospital. This sample will be processed for mutation analysis (DNA extraction from blood samples, mutation analysis) at the Clinical Molecular Diagnostic Laboratory at BC Children's Hospital. The techniques used in the pilot study will be implemented with the exception that microsatellite markers will not be used in order to save cost.
Using EXT 1 and EXT 2 primers (Appendix 1) both strands of a DNA segment are sequenced using ABI Big Dye chemistry Version 2. The resulting sequencing reaction products are then run on an ABI 3100 Avant genetic analyzer. Once a sequence is obtained it is analyzed with SeqScape version 2 software which allows comparison with reference sequence.
Data Analysis:
All information resulting from this research study will be kept strictly confidential. All documents will be identified by an ID number and kept in locked filing cabinets. Participants will not be identified by name in any reports of the completed study. Databases will be stored on project-dedicated laptop computer which is locked in the research office.
The phenotypic data collected will be used to describe family degrees (designed using Cyrillic software), phenotypes of affected individuals and mutations in the exostoses genes of interest (site and type of mutation). Subject heights and segment lengths will be converted to percentile figures to standardize for age and gender to allow for comparison amongst groups.
Genotypic data from the mutation analysis of blood samples will include location of the mutation (early in the gene versus late in the gene), type of mutation (alteration of gene as missense, frameshift, nonsense or splice site), and the amino acid change that was caused by the mutation. The data will be analyzed as follows:
Preliminary Analysis
- EXT 1 versus EXT 2
- Males versus Females
EXT 1 males versus EXT 1 females versus EXT 2 males versus EXT 2 females
Secondary Analysis
- Types of mutations (Missense versus Nonsense versus Splice site versus Frameshift)
- Early or late mutation (less than 1700 base pairs versus greater than 1700 base pairs)
With 2-way analyses, an unpaired t-test will be calculated and with greater than 2-way analyses, an ANOVA will be calculated. Power will be calculated for every comparison due to the huge variation in sample size. Statistical significance will be set to prior at 0.05 and power of 0.8.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- BC Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed with HME
Exclusion Criteria
- Subjects residing outside British Columbia for whom genetic testing and X-ray measurements cannot be taken onsite at BC Children's hospital
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
orthopedic symptoms as assessed by X-ray measurements
Time Frame: Post gene mutation identification
|
Post gene mutation identification
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Bone Diseases
- Neoplastic Syndromes, Hereditary
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Bone Diseases, Developmental
- Osteochondrodysplasias
- Hyperostosis
- Osteochondroma
- Exostoses, Multiple Hereditary
- Osteochondromatosis
- Exostoses
- Osteophyte
Other Study ID Numbers
- H04-70223
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exostoses, Multiple Hereditary
-
University of British ColumbiaChildren's & Women's Health Centre of British Columbia; Vancouver Foundation; Circle of CareTerminatedExostoses, Multiple HereditaryCanada
-
Istituto Ortopedico RizzoliCompletedExostoses, Multiple HereditaryItaly
-
University of British ColumbiaMHE CoalitionCompletedExostoses, Multiple HereditaryCanada
-
Istituto Ortopedico RizzoliCatholic University of the Sacred Heart; Regione Emilia-RomagnaCompletedOsteogenesis Imperfecta | Multiple Osteochondroma
-
Clementia Pharmaceuticals Inc.TerminatedExostoses, Multiple HereditaryUnited States, Spain, Canada, Japan, Italy, Portugal, United Kingdom, Turkey, Australia, Belgium, France, Netherlands
-
Istituto Ortopedico RizzoliCompletedOsteogenesis Imperfecta | Multiple Osteochondroma | Ollier Disease | Maffucci SyndromeItaly
-
Fundación Universidad Católica de Valencia San...Not yet recruiting
-
Masaryk Memorial Cancer InstituteRecruiting
-
Thammasat UniversityCompleted